Friday, 16 October 2026European Markets

NOVABASE,SGPS Stock 12.5% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with NOVABASE,SGPS (NBA.LS) rising 12.5% to €7.65 on Thursday, following the last session's upward trend. PSI dropped 0.37% to €6,924.65, after three sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

NOVABASE,SGPS's last close was €6.80, 26.54% above its 52-week high of €5.37.

About NOVABASE,SGPS

Novabase S.G.P.S., S.A., through its subsidiaries, provides IT consulting and services in Portugal, rest of Europe, Africa, the Middle East, and internationally. It operates through two segments, Next-Gen and Value Portfolio. The Next-Gen segment develops IT consulting and services to banks, insurance, capital markets, and telecommunication industries under the Celfocus brand name. The Value Portfolio segment is involved in venture capital activities. Novabase S.G.P.S., S.A. was incorporated in 1989 and is headquartered in Lisbon, Portugal.

Earnings Per Share

As for profitability, NOVABASE,SGPS has a trailing twelve months EPS of €0.11.

PE Ratio

NOVABASE,SGPS has a trailing twelve months price to earnings ratio of 69.55. Meaning, the purchaser of the share is investing €69.55 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.03%.

Volume

Today's last reported volume for NOVABASE,SGPS is 38396 which is 1129.84% above its average volume of 3122.

Revenue Growth

Year-on-year quarterly revenue growth grew by 16.9%, now sitting on 176.23M for the twelve trailing months.

More news about NOVABASE,SGPS (NBA.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com